Literature DB >> 11479717

Enzyme histochemically detectable NAD(P)H oxidase in human placental trophoblasts: normal, preeclamptic, and fetal growth restriction-complicated pregnancy.

S Matsubara1, I Sato.   

Abstract

The purpose of the present study was to determine the subcellular localization of NAD(P)H oxidase, a reactive oxygen species (ROS)-producing enzyme, in the human placenta at various gestational ages. Ultrastructural enzyme histochemistry for NAD(P)H oxidase, using cerium as a capturing agent, was carried out. Placentas from patients with severe preeclampsia and patients who delivered infants with fetal growth restriction (FGR) were also studied. Electron-dense precipitates indicating NAD(P)H oxidase activity were visible in the microvillous membranes of the placentas, especially on the surface plasma membrane of the syncytiotrophoblast microvilli, after 25 weeks of gestation. The distribution pattern and enzyme intensities were apparently the same among normal, preeclamptic, and FGR placentas. Cytochemical control experiments ensured the specific detection of NAD(P)H oxidase activity. These observations indicated that syncytiotrophoblasts possessed NAD(P)H oxidase activity, and thus ROS-generating activity. Placental NAD(P)H oxidase may play a role in placental lipid peroxidation and the placental defense mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479717     DOI: 10.1007/s004180100301

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  13 in total

Review 1.  Progress in focus: recent advances in histochemistry and cell biology.

Authors:  Esther Asan
Journal:  Histochem Cell Biol       Date:  2002-11-27       Impact factor: 4.304

2.  Oxidative stress and antioxidant defenses in pregnant women.

Authors:  Claudio A M Leal; Maria R C Schetinger; Daniela B R Leal; Vera M Morsch; Aleksandro Schafer da Silva; João F P Rezer; André Valle de Bairros; Jeandre Augusto Dos Santos Jaques
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

3.  Vascular endothelial mitochondrial oxidative stress in response to preeclampsia: a role for angiotension II type 1 autoantibodies.

Authors:  Evangeline Deer; V Ramana Vaka; Kristen M McMaster; Kedra Wallace; Denise C Cornelius; Lorena M Amaral; Mark W Cunningham; Babbette LaMarca
Journal:  Am J Obstet Gynecol MFM       Date:  2020-10-27

4.  Expression of NADPH oxidase isoform 1 (Nox1) in human placenta: involvement in preeclampsia.

Authors:  X-L Cui; D Brockman; B Campos; L Myatt
Journal:  Placenta       Date:  2005-07-01       Impact factor: 3.481

Review 5.  Review: Reactive oxygen and nitrogen species and functional adaptation of the placenta.

Authors:  L Myatt
Journal:  Placenta       Date:  2010-01-27       Impact factor: 3.481

6.  Rac1-dependent intracellular superoxide formation mediates vascular endothelial growth factor-induced placental angiogenesis in vitro.

Authors:  Su-min Li; Ling-wen Zeng; Lin Feng; Dong-bao Chen
Journal:  Endocrinology       Date:  2010-09-15       Impact factor: 4.736

7.  Immunohistochemical expression of von Willebrand factor in the preeclamptic placenta.

Authors:  Mauro Parra-Cordero; Cleofina Bosco; Jaime González; Rodrigo Gutiérrez; Pilar Barja; Ramón Rodrigo
Journal:  J Mol Histol       Date:  2011-08-17       Impact factor: 2.611

Review 8.  Oxidative stress in the placenta.

Authors:  Leslie Myatt; Xiaolan Cui
Journal:  Histochem Cell Biol       Date:  2004-07-10       Impact factor: 4.304

9.  Role of Mitochondrial Dysfunction and Reactive Oxygen Species in Mediating Hypertension in the Reduced Uterine Perfusion Pressure Rat Model of Preeclampsia.

Authors:  Venkata Ramana Vaka; Kristen M McMaster; Mark W Cunningham; Tarek Ibrahim; Rebekah Hazlewood; Nathan Usry; Denise C Cornelius; Lorena M Amaral; Babbette LaMarca
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

10.  Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia.

Authors:  Gene L Bidwell; Eric M George
Journal:  Front Pharmacol       Date:  2014-09-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.